Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
eNq1mF1v2jAUhu/5FVEudkdCoHSwJVQbazekVmNt0abdIJMcipmxU3/w0V8/h4BKJ0ddDb5M7Lzn2Of48avEF+sF8ZbABWY08aOg4XtAU5Zh+pD4o/urese/6NXiOVqi52lNPS+IIt9LCRIi8YvRYAKIiuDXzfUX0N8D93s1L2aTOaTyxTwlMQm+ITG7QXkxx4uXDGfeAuSMZYmfK7l968VCcp1Fb8X4H5GjFOJw9+ZwdD4+O3wfh4XYf6gqAfwa0QejKFArzVRxDlT2kYQHxjcV+bastLG4BcEUT2GI5GzI2RJnkBlDTBERYBVkusrugC8JyCKIUTycpwthJY7maH0LjwNz0p/0aF+uZb1Rj953ulGn0Wo1m+1zq1D8YKvMVdCLCNNxu9U5i9oh0JBsOE6RZWWGjEtEHNUEi/7LtnIUh8Pjq7XPsMgJ2gRzkdtuFeJIDwPXh9/dQooV3HONI6L37B99qggJ35j1aAcLRxkXLOozRWUFM0Z3thvRZ1TCurqidpiT610vYhCnk31i1Iz4oZoQnNoCTSNHgZCj20E1z06Hgs9IwIi7Y8FPTDO2EqdnzGFNHWWfbzFpFM15Fo2b3c551G5bH6HfuoEqbpdLxVkOoaYPFsdAZUCn7Fic6J40S+078kTNuHU4LEUEKjxO3ZIrugv3lsxZn7s7Q+WAUfTr5b1tc/xQwDd320ejNM6SfVntmOsC5LoTX8u7PLNJPm412p1u6+wdWuQf9945sfTJpagTm6y4GTAzKXPxIQxXq1UwQ6IukN7PYMqr8H9hXPgpFq9Z+1xLdz7eyc1fOqGSs45Sn5QX6NuKaHtqX/MGx/rd3fc7X22MIbmCI2pRAt4ZhgeXpyf7s9l1lvbwBWDchdkaUyQxo64sk5oYFY+6S3RZ6RXXfPg+neKK3yqVbRmH5S+dXi0Oi985vdpf+vT9lA==
E07dN7AvGFQ68dmT
